Eli Lilly over Novo Nordisk in GLP-1
Michael Farr argued for sticking with Eli Lilly over Novo Nordisk for GLP-1 exposure, despite finding Novo's valuation cheap.
CNBC FAST MONEY CHANGED ITS VIEW
BEARISH FOR 5 DAYS, THEN THE TURNKeep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.